Mobile element insertion detection in 89,874 clinical exomes.

Mendelian disease diagnostics exome sequencing mobile elements rare disease

Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
05 2020
Historique:
received: 08 10 2019
accepted: 07 01 2020
pubmed: 23 1 2020
medline: 28 4 2021
entrez: 23 1 2020
Statut: ppublish

Résumé

Exome sequencing (ES) is increasingly used for the diagnosis of rare genetic disease. However, some pathogenic sequence variants within the exome go undetected due to the technical difficulty of identifying them. Mobile element insertions (MEIs) are a known cause of genetic disease in humans but have been historically difficult to detect via ES and similar targeted sequencing methods. We developed and applied a novel MEI detection method prospectively to samples received for clinical ES beginning in November 2017. Positive MEI findings were confirmed by an orthogonal method and reported back to the ordering provider. In this study, we examined 89,874 samples from 38,871 cases. Diagnostic MEIs were present in 0.03% (95% binomial test confidence interval: 0.02-0.06%) of all cases and account for 0.15% (95% binomial test confidence interval: 0.08-0.25%) of cases with a molecular diagnosis. One diagnostic MEI was a novel founder event. Most patients with pathogenic MEIs had prior genetic testing, three of whom had previous negative DNA sequencing analysis of the diagnostic gene. MEI detection from ES is a valuable diagnostic tool, reveals molecular findings that may be undetected by other sequencing assays, and increases diagnostic yield by 0.15%.

Identifiants

pubmed: 31965078
doi: 10.1038/s41436-020-0749-x
pii: S1098-3600(21)00861-3
pmc: PMC7200591
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

974-978

Références

Mills RE, Bennett EA, Iskow RC, Devine SE. Which transposable elements are active in the human genome? Trends Genet. 2007;23:183–191.
doi: 10.1016/j.tig.2007.02.006
Bennett EA, Keller H, Mills RE, et al. Active Alu retrotransposons in the human genome. Genome Res. 2008;18:1875–1883.
doi: 10.1101/gr.081737.108
Brouha B, Schustak J, Badge RM, et al. Hot L1s account for the bulk of retrotransposition in the human population. Proc Natl Acad Sci USA. 2003;100:5280–5285.
doi: 10.1073/pnas.0831042100
Wang H, Xing J, Grover D, et al. SVA elements: a hominid-specific retroposon family. J Mol Biol. 2005;354:994–1007.
doi: 10.1016/j.jmb.2005.09.085
Gardner EJ, Prigmore E, Gallone G, et al. Contribution of retrotransposition to developmental disorders. Nat Commun. 2019;10:4630.
doi: 10.1038/s41467-019-12520-y
Kazazian HH, Wong C, Youssoufian H, Scott AF, Phillips DG, Antonarakis SE. Haemophilia A resulting from de novo insertion of L1 sequences represents a novel mechanism for mutation in man. Nature. 1988;332:164–166.
doi: 10.1038/332164a0
Hancks DC, Kazazian HH Jr. Roles for retrotransposon insertions in human disease. Mob DNA. 2016;7:9.
doi: 10.1186/s13100-016-0065-9
Qian Y, Mancini-DiNardo D, Judkins T, et al. Identification of pathogenic retrotransposon insertions in cancer predisposition genes. Cancer Genet. 2017;216–7:159–169.
doi: 10.1016/j.cancergen.2017.08.002
Watanabe M, Kobayashi K, Jin F, et al. Founder SVA retrotransposal insertion in Fukuyama-type congenital muscular dystrophy and its origin in Japanese and Northeast Asian populations. Am J Med Genet. 2005;138:344–348.
doi: 10.1002/ajmg.a.30978
Teugels E, De Brakeleer S, Goelen G, Lissens W, Sermijn E, De Grève J. De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. Hum Mutat. 2005;26:284.
doi: 10.1002/humu.9366
Tucker BA, Scheetz TE, Mullins RF, et al. Exome sequencing and analysis of induced pluripotent stem cells identify the cilia-related gene male germ cell-associated kinase (MAK) as a cause of retinitis pigmentosa. Proc Natl Acad Sci USA. 2011;108:E569–E576.
doi: 10.1073/pnas.1108918108
Vysotskaia VS, Hogan GJ, Gould GM, et al. Development and validation of a 36-gene sequencing assay for hereditary cancer risk assessment. PeerJ. 2017;5:e3046.
doi: 10.7717/peerj.3046
Chen J-M, Chuzhanova N, Stenson PD, Férec C, Cooper DN. Meta-analysis of gross insertions causing human genetic disease: novel mutational mechanisms and the role of replication slippage. Hum Mutat. 2005;25:207–221.
doi: 10.1002/humu.20133
Retterer K, Juusola J, Cho MT, et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med. 2016;18:696–704.
doi: 10.1038/gim.2015.148
Gardner EJ, Lam VK, Harris DN, et al. The Mobile Element Locator Tool (MELT): population-scale mobile element discovery and biology. Genome Res. 2017;27:1916–1929.
doi: 10.1101/gr.218032.116
Thung DT, de Ligt J, Vissers LE, et al. Mobster: accurate detection of mobile element insertions in next generation sequencing data. Genome Biol. 2014;15:488.
doi: 10.1186/s13059-014-0488-x
Colombo I, Finocchiaro G, Garavaglia B, et al. Mutations and polymorphisms of the gene encoding the beta-subunit of the electron transfer flavoprotein in three patients with glutaric acidemia type II. Hum Mol Genet. 1994;3:429–435.
doi: 10.1093/hmg/3.3.429
Wimmer K, Callens T, Wernstedt A, Messiaen L, Starink T. The NF1 gene contains hotspots for L1 endonuclease-dependent de novo insertion. PLoS Genet. 2011;7:e1002371.
doi: 10.1371/journal.pgen.1002371
Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. Nature. 2017;542:433–438.
doi: 10.1038/nature21062

Auteurs

Rebecca I Torene (RI)

GeneDx, Gaithersburg, MD, USA. rtorene@genedx.com.

Kevin Galens (K)

GeneDx, Gaithersburg, MD, USA.

Shuxi Liu (S)

GeneDx, Gaithersburg, MD, USA.

Kevin Arvai (K)

GeneDx, Gaithersburg, MD, USA.

Carlos Borroto (C)

GeneDx, Gaithersburg, MD, USA.

Julie Scuffins (J)

GeneDx, Gaithersburg, MD, USA.

Zhancheng Zhang (Z)

GeneDx, Gaithersburg, MD, USA.

Bethany Friedman (B)

GeneDx, Gaithersburg, MD, USA.

Hana Sroka (H)

GeneDx, Gaithersburg, MD, USA.

Jennifer Heeley (J)

Mercy Kids Genetics, St. Louis, MO, USA.

Erin Beaver (E)

Mercy Kids Genetics, St. Louis, MO, USA.

Lorne Clarke (L)

Provincial Medical Genetics Program, BC Women's Hospital + Health Centre, Vancouver, BC, Canada.

Sarah Neil (S)

Provincial Medical Genetics Program, BC Women's Hospital + Health Centre, Vancouver, BC, Canada.

Jagdeep Walia (J)

Divison of Medical Genetics, Kingston Health Sciences Centre, Kingston, ON, Canada.

Danna Hull (D)

Divison of Medical Genetics, Kingston Health Sciences Centre, Kingston, ON, Canada.

Jane Juusola (J)

GeneDx, Gaithersburg, MD, USA.

Kyle Retterer (K)

GeneDx, Gaithersburg, MD, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH